Aidea Pharma(SH:688488)2023-04-24 16:00Financial Performance - The company's revenue for Q1 2023 reached ¥112,621,308.59, representing a significant increase of 220.85% compared to the same period last year[4] - Net profit attributable to shareholders was ¥486,169.74, while the net profit after deducting non-recurring gains and losses was -¥5,449,520.91[4] - Total operating revenue for Q1 2023 reached CNY 112,621,308.59, a significant increase from CNY 35,101,031.38 in Q1 2022, representing a growth of 220.5%[21] - Net profit for Q1 2023 was CNY 486,169.74, a recovery from a net loss of CNY 22,302,749.04 in Q1 2022[22] - The company reported a gross profit margin of approximately 57.5% for Q1 2023, compared to 30.0% in Q1 2022[22] Cash Flow - The net cash flow from operating activities was -¥56,422,901.15, indicating increased cash outflows compared to the previous year[4] - Cash inflow from operating activities for Q1 2023 was CNY 67,546,626.96, a decrease of 18.8% from CNY 83,211,064.39 in Q1 2022[26] - Net cash outflow from operating activities was CNY -56,422,901.15, compared to CNY -25,653,518.27 in the same period last year[26] - Cash inflow from investment activities increased significantly to CNY 423,235,853.56 in Q1 2023, up from CNY 184,550,729.26 in Q1 2022[26] - Net cash flow from investment activities was CNY 101,645,922.92, a turnaround from a net outflow of CNY -210,694,569.73 in Q1 2022[26] - Cash inflow from financing activities was CNY 52,400,000.00, slightly up from CNY 50,000,000.00 in Q1 2022[27] - The total cash and cash equivalents at the end of Q1 2023 was CNY 186,643,934.15, compared to CNY 237,639,377.81 at the end of Q1 2022[27] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,697,708,847.37, reflecting a 2.57% increase from the end of the previous year[5] - Total liabilities increased to CNY 495,282,021.64 in Q1 2023 from CNY 456,230,439.66 in Q1 2022, marking an increase of 8.6%[19] - The company’s total current assets reached CNY 827.82 million, slightly up from CNY 802.46 million at the end of the previous year[16] - The company’s long-term equity investments were reported at CNY 90.58 million[17] - The company has long-term borrowings of 60,000,000.00, indicating reliance on debt financing[31] Research and Development - R&D investment totaled ¥15,488,455.18, which decreased by 22.78% year-on-year, and accounted for 13.75% of revenue, a reduction of 43.39 percentage points[4][7] - Research and development expenses for Q1 2023 were CNY 9,828,619.27, down from CNY 13,727,379.60 in Q1 2022, indicating a decrease of 28.5%[22] Company Developments - The company received approval for its innovative drug AINOMI tablets, marking a significant milestone in the HIV treatment field[12] - The company aims to enhance its product pipeline and maintain its first-mover advantage in the HIV treatment sector with the launch of AINOMI tablets[13] - The company has strengthened its talent pool by hiring several senior management personnel, including a Chief Operating Officer and a Chief Medical Officer[14] Financial Reporting - The company did not conduct an audit for the Q1 financial statements[3] - The report was published by the board of directors on April 24, 2023, indicating the date of financial disclosure[31] - The company implemented new accounting standards starting January 1, 2023, affecting the financial statements[27]